Hematology Oncology Edition: Top Headlines for Week of November 7, 2022

In this edition, FDA approves Tecvayli for multiple myeloma, radiation and hormone therapy slows progression of prostate cancer, and more.

Read the full coverage here:

FDA approves Tecvayli for advanced multiple myeloma

Adding radiation to hormone therapy slows progression of oligometastatic prostate cancer

Use of cannabis during cancer treatment may have ‘under-appreciated’ financial impact

Older cancer survivors at higher risk for bone fracture

Machine-learning approach using step counts predicts hospitalization during radiotherapy

References:

Chino F, et al. Abstract 24. Presented at: ASCO Quality Care Symposium; Sept. 30-Oct. 1, 2022; Chicago.

Friesner I, et al. Abstract 132. Presented at: American Society for Radiation Oncology Annual Meeting; Oct. 23-26, 2022; New Orleans.

Press Release

Rees-Punia E, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.5153.

Tang C, et al. Abstract LBA 05. Presented at: American Society for Radiation Oncology Annual Meeting; Oct. 23-26, 2022; San Antonio.